Lilly is set to construct a $6.5 billion factory in Houston for the production of its first obesity medication.

Eli Lilly announced plans to construct a $6.5 billion manufacturing facility in Houston, focused on producing active pharmaceutical ingredients, including orforglipron, a potential obesity treatment. The 236-acre site will create 615 full-time jobs and is part of Lilly's initiative to enhance domestic medicine production, with three additional U.S. facilities planned. The Houston project, supported by a $5.5 million Texas Enterprise Fund grant, aims to strengthen Lilly’s manufacturing capabilities and will incorporate advanced technologies.